<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740697</url>
  </required_header>
  <id_info>
    <org_study_id>20 SEIN 13</org_study_id>
    <nct_id>NCT04740697</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer</brief_title>
  <acronym>EUTACAM</acronym>
  <official_title>Pilot Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a&#xD;
      real-life situation, adherence to tamoxifen treatment as a function of the taking of&#xD;
      alternative and complementary therapies in patients with localized hormone-dependent breast&#xD;
      cancer.&#xD;
&#xD;
      200 patients will be included in the study.&#xD;
&#xD;
      Each patient will be followed for one day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients who adhere to tamoxifen treatment.</measure>
    <time_frame>18 months after the start of the research</time_frame>
    <description>This outcome will be assessed by the completion of the GIRERD questionnaire by the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients taking ACT.</measure>
    <time_frame>18 months after the start of the research</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients consuming turmeric-based dietary supplements.</measure>
    <time_frame>18 months after the start of the research</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of tamoxifen in patients.</measure>
    <time_frame>18 months after the start of the research</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patient with localized breast cancer.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.</intervention_name>
    <description>Each included patient will be referred to the health care staff for a blood sample:&#xD;
for the determination of the residual plasma concentration of tamoxifen and its active metabolites,&#xD;
for the constitution of a biobank.&#xD;
Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...).</description>
    <arm_group_label>Patient with localized breast cancer.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years at entry into the study.&#xD;
&#xD;
          2. Patient treated for hormone-dependent localized breast cancer requiring adjuvant&#xD;
             Hormonal Therapy (HT) with tamoxifen.&#xD;
&#xD;
          3. Patients treated with tamoxifen for a maximum of 1 to 3 years.&#xD;
&#xD;
          4. Patient affiliated with a Social Security system in France.&#xD;
&#xD;
          5. Patients who signed informed consent prior to inclusion in the study and prior to any&#xD;
             specific study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding women.&#xD;
&#xD;
          2. Any psychological, family, geographical or sociological condition that does not allow&#xD;
             the medical follow-up and/or the procedures foreseen in the study protocol to be&#xD;
             respected.&#xD;
&#xD;
          3. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under legal protection (curatorship and guardianship, protection of justice).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence DALENC</last_name>
    <phone>05 31 15 51 04</phone>
    <email>dalenc.florence@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DALENC</last_name>
      <phone>05 31 15 51 04</phone>
      <email>dalenc.florence@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Alternative and complementary therapies</keyword>
  <keyword>Treatment adherence</keyword>
  <keyword>Turmeric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

